35625926|t|Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin.
35625926|a|The oxidative stress phenomenon is a result of anticancer therapy. The aim of this study was the assessment of gene expression profile changes, and to determine the miRNAs regulating genes' transcriptional activity in an Ishikawa endometrial cancer culture exposed to cisplatin or salinomycin, compared to a control culture. The molecular analysis comprised the microarray technique (mRNAs and micro RNA (miRNA), the real-time quantitative reverse transcription reaction (RTqPCR), enzyme-linked immunosorbent assay (ELISA) reactions, and Western blot. NR4A2, MAP3K8, ICAM1, IL21, CXCL8, CCL7, and SLC7A11 were statistically significantly differentiated depending not only on time, but also on the drug used in the experiment. The conducted assessment indicated that the strongest links were between NR4A2 and hsa-miR-30a-5p and has-miR-302e, MAP3K8 and hsa-miR-144-3p, CXCL8 and hsa-miR-140-3p, and SLC7A11 and hsa-miR-144-3p. The obtained results suggest that four mRNAs-NR4A2, MAP3K8, CXCL8 and SLC7A11-and four miRNAs-hsa-miR-30a-5p, hsa-miR-302e, hsa-miR-144-3p and hsa-miR-140-3-changed their expressions regardless of the chemotherapeutic agent used, which suggests the possibility of their use in monitoring the severity of oxidative stress in endometrial cancer. However, considering the results at both the mRNA and the protein level, it is most likely that the expressions of NR4A2, MAP3K8, CXCL8 and SLC7A11 are regulated by miRNA molecules as well as other epigenetic mechanisms.
35625926	89	97	Ishikawa	CellLine	CVCL:2529
35625926	123	132	Cisplatin	Chemical	MESH:D002945
35625926	136	147	Salinomycin	Chemical	MESH:C010327
35625926	370	378	Ishikawa	CellLine	CVCL:2529
35625926	379	397	endometrial cancer	Disease	MESH:D016889
35625926	417	426	cisplatin	Chemical	MESH:D002945
35625926	430	441	salinomycin	Chemical	MESH:C010327
35625926	701	706	NR4A2	Gene	4929
35625926	708	714	MAP3K8	Gene	1326
35625926	716	721	ICAM1	Gene	3383
35625926	723	727	IL21	Gene	59067
35625926	729	734	CXCL8	Gene	3576
35625926	736	740	CCL7	Gene	6354
35625926	746	753	SLC7A11	Gene	23657
35625926	948	953	NR4A2	Gene	4929
35625926	958	969	hsa-miR-30a	Gene	407029
35625926	981	989	miR-302e	Gene	100313774
35625926	991	997	MAP3K8	Gene	1326
35625926	1018	1023	CXCL8	Gene	3576
35625926	1028	1039	hsa-miR-140	Gene	406932
35625926	1048	1055	SLC7A11	Gene	23657
35625926	1072	1074	3p	Chromosome	3
35625926	1121	1126	NR4A2	Gene	4929
35625926	1128	1134	MAP3K8	Gene	1326
35625926	1136	1141	CXCL8	Gene	3576
35625926	1146	1153	SLC7A11	Gene	23657
35625926	1170	1181	hsa-miR-30a	Gene	407029
35625926	1186	1198	hsa-miR-302e	Gene	100313774
35625926	1400	1418	endometrial cancer	Disease	MESH:D016889
35625926	1535	1540	NR4A2	Gene	4929
35625926	1542	1548	MAP3K8	Gene	1326
35625926	1550	1555	CXCL8	Gene	3576
35625926	1560	1567	SLC7A11	Gene	23657
35625926	Association	406932	4929
35625926	Negative_Correlation	MESH:D002945	MESH:D016889
35625926	Association	MESH:D016889	1326
35625926	Association	3576	406932
35625926	Association	407029	4929
35625926	Association	MESH:D016889	100313774
35625926	Association	MESH:D016889	3576
35625926	Association	MESH:D016889	4929
35625926	Negative_Correlation	MESH:C010327	MESH:D016889
35625926	Association	MESH:D016889	23657
35625926	Association	MESH:D016889	407029

